HERTHENA-Lung01 is a Phase 2 clinical trial (NCT04619004) aimed at evaluating the anti-tumor activity of patritumab deruxtecan in subjects with metastatic or locally advanced NSCLC and an activating EGFR mutant (exon 19 deletion or L858R). Here, EGFR is linked to non-small cell lung carcinoma.